Gonadoblastoma with Dysgerminoma in a Virilized Adolescent with Karyotype 46,XX: A Case Report and Review of the Literature

Hyperandrogenism and the resulting manifestations in young female children can stem from various inherited and acquired causes. In some cases, androgen-producing tumors in the ovaries or adrenal glands can quickly lead to virilization. Gonadoblastomas are uncommon ovarian tumors composed of sex cord and primitive germ cell components. While gonadoblastomas are typically benign, they are often found alongside invasive germ cell malignancies. Typically, the tumor is observed in individuals with certain gonadal gene mutation syndromes, such as pure or mixed gonadal dysgenesis. The majority of gonadoblastomas are found in individuals with 46,XY gonadal dysgenesis, as well as in females carrying Y chromosome material. However, it is exceptionally rare for gonadoblastoma to occur in women with a normal 46,XX karyotype (1, 2). We present a case report of a 14.5-year-old girl with a normal 46,XX karyotype who was diagnosed with gonadoblastoma accompanied by dysgerminoma. We describe the clinical symptoms exhibited by the patient and the outcome of her treatment, along with a comprehensive analysis of previously reported cases of gonadoblastoma occurring in individuals with a typical 46,XX karyotype.

A 14.5-year-old girl was referred to our outpatient clinic because of significant hirsutism developing over the preceeding two months. She was born at term, appropriate for gestational age, to first-degree consanguineous parents after an uneventful pregnancy, and her developmental milestones were normal. Puberty began at the age of 10.5 years, but menarche has not yet occurred.

At presentation, her weight, height, and body mass index (BMI) were 42.7 kg [-1.95 standard deviation score (SDS)], 158.1 cm (-0.5 SDS), and 17.08 kg/m² (1.85 SDS), respectively. The pubertal stage was Tanner 4, and her external genitalia were remarkable for marked clitoromegaly, measuring 1.5x1 cm, with symmetrical labioscrotal folds and no palpable gonads. The modified Ferriman-Gallwey (mFG) score was 16, and a significant deepening of her voice was notable. Otherwise, the systemic examination was normal.

Hormonal evaluation revealed high serum luteinizing hormone (43.4 mIU/L) and follicle-stimulating hormone (87.6 mIU/L) levels, confirming the diagnosis of hypergonadotropic hypogonadism. In addition, serum total testosterone concentration was elevated (1.07 ng/mL). Basal levels of androgen precursors were normal (see Table 1), and adrenal-derived hyperandrogenism was ruled out with a normal response to a corticotropin stimulation test. Tumor markers, including b-human chorionic gonadotropin (β-hCG), α-fetoprotein (αFP), and lactate dehydrogenase (LDH), were normal. Abdominal ultrasound (US) showed no abnormalities, and bilateral adrenal glands were normal. Pelvic US showed that the size of the uterus and ovaries were appropriate for the pubertal stage. In this hypergonadotropic hypogonadism patient with hyperandrogenism, cytogenetic analysis revealed a normal female karyotype (46,XX).

Unfortunately, the patient missed follow-up visits for two years. At the age of 16.3 years, she was re-evaluated. During the past two years, she had become increasingly uncomfortable due to progressive hirsutism and needed laser hair removal session every two weeks on her whole body. At this time, the mFG score was 22, and clitoral length was measured at 3 cm. Fibrotic ovarian tissue was detected; however, no abdominal or gonadal mass was visualised on US. Abdominal magnetic resonance imaging (MRI) revealed similar findings (as shown in Table 1). Fluorescence in situ hybridization analysis showed no alterations in the SRY gene. Polymerase chain reaction (PCR) analysis for the SRY gene sequence in the DNA sample obtained from ovarian tissue did not show the presence of SRY. In addition, whole exome sequencing was performed to comprehensively assess all known genetic disorders, with a particular focus on sex-determining genes, such as WT1, SOX9, and DAX1. A laparoscopic gonad biopsy was performed and it revealed bilateral gonadoblastoma and unilateral (left) dysgerminoma. Ultimately, the patient underwent bilateral oophorectomy. Macroscopic pathological examination of the salpingo-oophorectomy material revealed a right ovary measuring 3×1×0.5 cm, while the left ovary was slightly larger, measuring 2.7×1.5×3 cm.

Histopathological microscopic analysis provided further insight into the cellular composition. The specimen revealed the presence of primitive germ cells alongside sex cord stromal cells, surrounded by ovarian-type stroma. Notably, morphological analysis identified a dysgerminoma in the left ovary. This tumor exhibited characteristic cell cords, featuring both clear and eosinophilic cytoplasm, and measured approximately 0.5 cm in diameter. Immunohistochemical staining was performed to further classify the cellular components. The sex cord cells within the gonadoblastoma stained positively for inhibin, confirming their identity. In contrast, the germ cells within the dysgerminoma stained positively for C-kit, which is a known marker for germ cell tumors. These staining patterns facilitated the differentiation of the various cell types present within the tumor (see Figure 1). No pathological F-18 fluorodeoxyglucose uptake was detected on positron emission tomography/computed tomography, and she did not require or receive any chemotherapy. The bone mineral density z-score was -1.7, and hormone replacement therapy was commenced following gonadectomy. Pelvic MRI and tumor markers were subsequently checked at 6-month intervals, with no abnormal findings evident.

We describe a girl with a 46,XX karyotype who exhibited virilization, a condition rarely caused by gonadoblastoma. The etiology of virilization in this girl was clinically challenging due to the variety of potential causes. Various inherited and acquired conditions may contribute to virilization, including disorders of sex development (DSD), virilizing ovarian tumors, adrenal tumors, and exposure to exogenous androgens. Among the DSD conditions, different forms of congenital adrenal hyperplasia, ovotesticular DSD, and aromatase deficiency may manifest with hyperandrogenic features in females. These conditions contribute to the clinical spectrum of causes that need to be considered when evaluating virilization in a young girl. The severity of virilization served as an important clinical indicator, suggesting an ovarian cause as the underlying factor in this girl. The rapid and severe nature of the virilization, combined with the exclusion of adrenal causes by a normal corticotropin stimulation test and normal adrenal precursor levels, directed the clinical suspicion toward an androgen-secreting ovarian tumor.

Gonadoblastoma was first recognized as a distinct entity by Scully (1) in 1953. Histologically, it is characterized by the presence of distinct clusters consisting of germ cells and sex cord elements that resemble immature Sertoli or granulosa cells. Histopathologically, the present case exhibited sex cord cells in the gonadoblastoma and germ cells in the dysgerminoma.

Gonadoblastoma has a high incidence in patients with various syndromes of gonadal maldevelopment that are characterized by the presence of the Y chromosome (2). Gonadoblastomas are observed in approximately 25% to 30% of patients with XY gonadal dysgenesis and in approximately 15% to 20% of individuals with a karyotype of 45,X/46,XY (2). However, a number of cases have been reported in females with a normal 46,XX karyotype. Pratt-Thomas and Cooper (3) reported a case where unilateral gonadoblastoma that was found in association with a ruptured ectopic tubal pregnancy, and the cytogenetic evaluation of peripheral leukocytes revealed a karyotype of 46,XX/45,XO.

In individuals with a 46,XX karyotype, the mechanism underlying the development of gonadoblastoma in the absence of a Y chromosome remains unclear. However, potential contributing factors may include somatic mutations, epigenetic changes, or hormonal influences. Somatic mutations in genes such as WT1 and SF1 may disrupt gonadal development, leading to tumorigenesis. Epigenetic alterations, including DNA methylation or histone modifications, may silence or activate genes inappropriately, leading to abnormal gonadal development (4, 5). Hormonal influences, such as elevated gonadotropin levels, are thought to potentially play a role in the development of gonadoblastoma but the precise mechanisms underlying this association have yet to be fully elucidated (6). Future studies are essential to elucidate these alternative pathways, and understanding such mechanisms may reveal novel targets for early detection and treatment in the 46,XX population of patients with gonadoblastoma.

While gonadoblastomas are typically considered benign, they often coexist with invasive germ cell malignant tumors. The most prevalent malignancy found in association with gonadoblastomas is pure dysgerminoma. However, other variants, such as immature teratoma, embryonal carcinoma, yolk sac tumor, and choriocarcinoma, have also been reported. In Scully’s review of 74 gonadoblastoma cases approximately 50% of the tumors were accompanied by dysgerminoma as a coexisting germ cell tumor. This is similar to the presented case and consistent with previous studies. Other types of germ cell tumors, such as embryonal carcinoma, yolk sac tumor, and teratoma, were also reported in a few cases (1, 7).

In our review of the literature since 1990, we identified 14 cases of gonadoblastoma in females with a normal 46,XX karyotype (7,8,9,10,11,12,13,14,15,16,17,18,19,20). Table 2 presents a summary of the clinical characteristics observed in these 14 cases as documented in the literature and also includes the presented case for comparison. While abdominal symptoms, such as abdominal pain or the presence of a mass, were the most common complaints in the 15 reported cases (66%, 10/15 cases), it is important to note that cases have also presented with symptoms such as vaginal bleeding, menstrual disorders, and virilization. Our case unusual because of several distinctive findings. Firstly, there was an absence of abdominal pain, which is a common complaint in similar cases. Moreover, both physical examination and imaging tests (US and MRI) did not identify any masses. Furthermore, the levels of tumor markers, including αFP, β-HCG, and LDH were not significantly elevated. Given these unique characteristics, an important aspect of the present case was that the diagnosis made through diagnostic laparoscopy. In the case reported by Chandrapattan et al. (19), and similar to our case, the chief complaint was virilization. Furthermore, contrasexual pubertal development was observed in that particular case.

In individuals with partial or complete gonadal dysgenesis, preventive bilateral gonadectomy is commonly recommended due to the markedly increased risk of gonadal malignancy (15% to 50%) associated with the presence of the Y chromosome (20). Therefore, it is important to confirm if Y chromosomal material is present or not. Typically, peripheral blood lymphocyte karyotyping is performed to detect Y chromosomes in the germline but this approach carries the risk of missing small chromosomal fragments containing Y chromosome material. In the presented case, PCR analysis for the SRY gene sequence in the DNA sample obtained from the ovarian tissue did not demonstrate the presence of SRY.

Surgery is the primary treatment method for the management of gonadoblastomas. The specific surgical approach may vary depending on the extent and characteristics of the tumor. It is important to consider individual patient factors and provide appropriate adjunct therapies, such as chemotherapy, to support the overall treatment plan. Out of the 14 previously documented cases, chemotherapy was administered in nine (64.3%) cases. Due to the localized and small nature of the tumor in our patient, chemotherapy was deemed unnecessary.

It is important to consider that when managing hirsutism and progressive virilization, laparoscopy should be performed so that biopsies may provide guidance when imaging methods and laboratory tests fail to yield a definitive diagnosis. Further studies are needed to elucidate the etiopathogenesis of reported cases.